Fig. 1 · Structure

Documents & Downloads

Tretinoin (Retinoic acid)

Cat. No. A10944 CAS 302-79-4

RAR agonist

Tretinoin is an endogenous agonist for retinoic acid receptors with IC50 value of 14 nM for RAR-alpha, RAR-beta and RAR-gamma receptors).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
RAR
RXR

Cellular Effect

Cell Line Activity Value Description Reference
3LLD122 IC50 33 μM Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50% [PMID: 10956204]
COLO 205 IC50 37 μM Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay [PMID: 20405849]
COS-7 EC50 0.2 nM Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay [PMID: 19058965]
COS-7 EC50 0.6 nM Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay [PMID: 30792038]
COS-7 EC50 1.2 nM Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay [PMID: 30792038]
COS-7 EC50 1.2 nM Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay [PMID: 30792038]
COS-7 EC50 12 nM Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay [PMID: 19058965]
COS-7 EC50 17 nM Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay [PMID: 19058965]
CV-1 EC50 0.7 nM Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay 10.1016/0960-894X(95)00588-K
CV-1 EC50 1 nM Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay 10.1016/0960-894X(95)00588-K
CV-1 EC50 1100 nM Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay 10.1016/0960-894X(95)00588-K
CV-1 EC50 1400 nM Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay 10.1016/0960-894X(95)00588-K
CV-1 EC50 7 nM Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay 10.1016/0960-894X(95)00588-K
CV-1 EC50 900 nM Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay 10.1016/0960-894X(95)00588-K
CWR22R GI50 25.11 μM Growth inhibition of human CWR22Rv1 cells by MTT assay [PMID: 25634130]
DU-145 GI50 11.64 μM Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 25701251]
F9 IC50 0.1 nM Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days [PMID: 17489579]
F9 ED50 0.1 nM Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay [PMID: 2738885]
Fibroblast IC50 10 μM Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs [PMID: 18029185]

19 records · Scroll to view more

Tretinoin (Retinoic acid) Research Summary

This section summarizes 3 in vitro studies of Tretinoin (Retinoic acid) from 2 published references. In vitro models include J1 mouse ESCs.

Tretinoin (Retinoic acid) In Vitro Studies

In fully grown skin rafts, overnight supplementation with Tretinoin induced RDH10 expression in human epidermis compared with vehicle supplied in culture medium. In J1 mouse ESCs, Tretinoin treatment significantly downregulated 1132 genes and significantly upregulated 1093 genes, as assessed by microarray analysis. sRNA sequencing in Tretinoin-treated J1 mouse ESCs identified 31 miRNAs significantly upregulated and 175 miRNAs significantly downregulated. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

RDH10 transcript induction in human epidermal skin rafts

Cell-based study · fully grown skin rafts; four rafts [1]

Fully grown skin rafts received Tretinoin at 0.1 μM in culture medium overnight. Compared with vehicle supplied in culture medium, treatment induced RDH10 expression in human epidermis, assessed by qPCR.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
levels of RDH10 transcripts by qPCRReported result ATRA induced the expression of RDH10 in human epidermis[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 μM
Exposure duration
overnight
Method
supplemented skin raft culture medium
Co-treatment
Other interventions in this design: cholera toxin; insulin; apo-transferrin; hydrocortisone-21; human epidermal growth factor. Compound effect isolated by the comparison: vehicle supplied in culture medium.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Tretinoin; Compound label in the paper: ATRA

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > 1. Preparation of organotypic skin rafts and treatment with UAB30 or bexarotene (S6, S9, S10); Materials and Methods > 4. QPCR analysis (S48); Results (S114, S115)

levels of RDH10 transcripts by qPCR: levels of RDH10 transcripts by qPCR; comparator: vehicle supplied in culture medium — Results (S114, S115)

Gene expression changes in mouse embryonic stem cells

Cell-based study · J1 mouse ESCs [2]

J1 mouse ESCs received Tretinoin at 1 μM for 24 h, with an equal volume of DMSO as control. Gene expression microarray analysis identified 1132 significantly downregulated genes and 1093 significantly upregulated genes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
gene expression microarray analysisgene expression 1132 genes that were significantly downregulated[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
24 h
Method
added to mESCs
Vehicle
dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: Tretinoin; Compound label in the paper: Retinoic Acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Microarray profiling demonstrates that RA induces ectodermal marker expression in ES cells (S5, S6); Materials and Methods > Cell culture and treatment (S65, S66); Materials and Methods > RNA isolation, microarrays and sRNA high-throughput sequencing (S77, S78)

gene expression microarray analysis: gene expression microarray analysis; comparator: an equal volume of DMSO — Results > Microarray profiling demonstrates that RA induces ectodermal marker expression in ES cells (S5, S6)

MicroRNA expression changes in mouse embryonic stem cells

Cell-based study · J1 mouse ESCs [2]

J1 mouse ESCs received Tretinoin at 1 μM for 24 h, with an equal volume of DMSO as control. sRNA sequencing identified 31 significantly upregulated miRNAs and 175 significantly downregulated miRNAs.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
sRNA sequencingmiRNA expression 175 miRNAs that were significantly downregulated[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
24 h
Method
added to mESCs
Vehicle
dimethyl sulfoxide (DMSO)
Methods and source locations

Compound reported in the paper: Tretinoin; Compound label in the paper: Retinoic Acid

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Multiple microRNA are suppressed in mESCs by RA treatment (S40, S41); Materials and Methods > Cell culture and treatment (S65, S66); Materials and Methods > RNA isolation, microarrays and sRNA high-throughput sequencing (S77, S78)

sRNA sequencing: sRNA sequencing; comparator: an equal volume of DMSO — Results > Multiple microRNA are suppressed in mESCs by RA treatment (S40, S41)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 302-79-4
Applications RAR agonist
Formula C20H28O2
Molecular Weight 300.4
Synonyms Retinoic Acid; ATRA; Vitamin A Acid
SMILES
CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 57 mg/mL (189.74 mM)
Water Insoluble
Ethanol 6 mg/mL (19.97 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tretinoin (Retinoic acid) Research References

  1. [1] Wu L, Chaudhary SC, Atigadda VR, et al. Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis. PLoS One (2016). PMID: 27078158 DOI: 10.1371/journal.pone.0153556 Source material
  2. [2] Zhang J, Gao Y, Yu M, et al. Retinoic Acid Induces Embryonic Stem Cell Differentiation by Altering Both Encoding RNA and microRNA Expression. PLoS One (2015). PMID: 26162091 DOI: 10.1371/journal.pone.0132566 Source material

Added to your cart

View Cart Checkout
Loading...